Teva Pharmaceutical (Four Oncology R&D Assets)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Four oncology development programs of Teva Pharmaceutical Industries. The business assets are CEP-32496, a potent small molecule inhibitor of BRAF, EGFR and RET, CEP-40783, a potent, highly selective, pseudo-irreversible inhibitor of AXL and cMET, CEP-40125, a nanoformulation of a modified bendamustine with potential activity in solid tumors and TEV-44229, a potent, selective inhibitor of the atypical kinase PKCiota that is in preclinical studies.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- San Diego, CA 92121
- United States
Teva Pharmaceutical (Four Oncology R&D Assets) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.
Request full access to PitchBookTeva Pharmaceutical (Four Oncology R&D Assets) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.
Request full access to PitchBook